JPRN-UMIN000021138
Recruiting
N/A
Efficacy and safety of anticoagulant treatment using New oral anticoagulant (edoxaban) in atrial fibrillation after cardiac surgery. - Efficacy and safety of anticoagulant treatment using new alternative antithrombotic agents in atrial fibrillation after cardiac surgery.
ihon University school of medicine0 sites150 target enrollmentFebruary 23, 2016
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- arterial fibrillation after cardiac surgery (nonvalvular disease)
- Sponsor
- ihon University school of medicine
- Enrollment
- 150
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •past of arrhythmia cardiogenic shock NYHA class IV congestive heart failure despite treatment sinus bradycardia at rest (\<50/min) second \-or third\-degree AV block clinical hypothyroidism or hyperthyroidism Doctor's decision not to register to this regimen
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
Efficacy and safety of anticoagulant treatment using new alternative antithrombotic agents in acute cardioembolic stroke with nonvalvular atrial fibrillation.cerebral infarctionJPRN-UMIN000010477Department of Neurology, Kansai Medical University50
Not Yet Recruiting
N/A
The efficacy and safety of anticoagulant therapy Arixtra Injection for the prevention of the vein thromboembolism in laparoscopic colorectal surgerycolorectal cancerJPRN-UMIN000007005Osaka Medical College200
Completed
N/A
A Study of Safety and efficacy of anticoagulant therapy in the treatment of Atrial Fibrillation in KANAGAWAAtrial fibrillationJPRN-UMIN000011830ASSAF-K steering committee5,000
Not Yet Recruiting
Phase 3
Effectiveness and safety of blood thinning agent (Anticoagulation) in patients with dying limb with poor blood supply (Digital Gangrene) and an underlying immune system related disease (Connective Tissue Disease)Health Condition 1: M339- Dermatopolymyositis, unspecifiedHealth Condition 2: M319- Necrotizing vasculopathy, unspecifiedHealth Condition 3: M340- Progressive systemic sclerosisHealth Condition 4: M368- Systemic disorders of connective tissue in other diseases classified elsewhereHealth Condition 5: M359- Systemic involvement of connectivetissue, unspecifiedHealth Condition 6: M321- Systemic lupus erythematosus withorgan or system involvementCTRI/2024/03/063481Department of Clinical Immunology & Rheumatology
Completed
N/A
The efficacy of pro- and anticoagulant therapy in plasma from patients with liver cirrhosis .coagulation.hemostasis10064477NL-OMON37417niversitair Medisch Centrum Groningen126